Giovanna Bergamini
GSK company, Germany
Title: CZ415, a highly selective mTOR inhibitor showing in vivo efficacy in a collagen induced arthritis (CIA) model
Biography
Biography: Giovanna Bergamini
Abstract
CZ415, a potent ATP-competitive mTOR inhibitor with unprecedented selectivity over other kinases will be presented here. It’s in vivo pharmacokinetic profile will be reported, in addition to a comprehensive characterization of its in vitro activities and ADME data. The suitability of this inhibitor for studying in vivo mTOR biology is shown by the inhibition of target-dependent phosphorylation signaling observed in a mechanistic mouse model following oral administration. The compound reported here is the first ATP-competitive mTOR inhibitor described to show efficacy in a semi-therapeutic collagen induced arthritis (CIA) mouse model
